[1]. Baud D,Qi X,Nielsen-Saines K,Musso D,Pomar L,Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020; 20: 773.
[2]. Shen B,Yi X,Sun Y,Bi X,Du J,Zhang C, et al. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. Cell. 2020; 182: 59-72.e15.
[3]. Aceti A,Margarucci L M,Scaramucci E,Orsini M,Salerno G,Di Sante G, et al. Serum S100B protein as a marker of severity in Covid-19 patients. Sci Rep. 2020; 10: 18665.
[4]. Ren H,Yang Y,Wang F,Yan Y,Shi X,Dong K, et al. Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiovasc Diabetol. 2020; 19: 58.
[5]. Zheng J,Wong L R,Li K,Verma A K,Ortiz M E,Wohlford-Lenane C, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021; 589: 603-607.
[6]. Mrityunjaya M,Pavithra V,Neelam R,Janhavi P,Halami P M,Ravindra P V. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19. Front Immunol. 2020; 11: 570122.
[7]. Fathi F,Sami R,Mozafarpoor S,Hafezi H,Motedayyen H,Arefnezhad R, et al. Immune system changes during COVID-19 recovery play key role in determining disease severity. Int J Immunopathol Pharmacol. 2020; 34: 2058738420966497.
[8]. Paces J,Strizova Z,Smrz D,Cerny J. COVID-19 and the immune system. Physiol Res. 2020; 69: 379-388.
[9]. Maggi E,Canonica G W,Moretta L. COVID-19: Unanswered questions on immune response and pathogenesis. J Allergy Clin Immunol. 2020; 146: 18-22.
[10]. Hosseini A,Hashemi V,Shomali N,Asghari F,Gharibi T,Akbari M, et al. Innate and adaptive immune responses against coronavirus. Biomed Pharmacother. 2020; 132: 110859.
[11]. Toor S M,Saleh R,Sasidharan Nair V,Taha R Z,Elkord E. T-cell responses and therapies against SARS-CoV-2 infection. Immunology. 2021; 162: 30-43.
[12]. van Eeden C,Khan L,Osman M S,Cohen Tervaert J W. Natural Killer Cell Dysfunction and Its Role in COVID-19. Int J Mol Sci. 2020; 21.
[13]. Burgess S J,Maasho K,Masilamani M,Narayanan S,Borrego F,Coligan J E. The NKG2D receptor: immunobiology and clinical implications. Immunol Res. 2008; 40: 18-34.
[14]. Liu H,Osterburg A R,Flury J,Huang S,McCormack F X,Cormier S A, et al. NKG2D Regulation of Lung Pathology and Dendritic Cell Function Following Respiratory Syncytial Virus Infection. J Infect Dis. 2018; 218: 1822-1832.
[15]. Babic M,Dimitropoulos C,Hammer Q,Stehle C,Heinrich F,Sarsenbayeva A, et al. NK cell receptor NKG2D enforces proinflammatory features and pathogenicity of Th1 and Th17 cells. J Exp Med. 2020; 217.
[16]. Groh V,Wu J,Yee C,Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002; 419: 734-738.
[17]. Luo Q,Guo X,Peng S,Luo W,Tian F,Yu P, et al. The association between MICA/MICB polymorphism and respiratory syncytial virus infection in children. Int J Immunogenet. 2017; 44: 328-336.
[18]. Zdrenghea M T,Mallia P,Johnston S L. Immunological pathways in virus-induced COPD exacerbations: a role for IL-15. Eur J Clin Invest. 2012; 42: 1010-1015.
[19]. Zdrenghea M T,Telcian A G,Laza-Stanca V,Bellettato C M,Edwards M R,Nikonova A, et al. RSV infection modulates IL-15 production and MICA levels in respiratory epithelial cells. Eur Respir J. 2012; 39: 712-720.
[20]. Zhang X,Tan Y,Ling Y,Lu G,Liu F,Yi Z, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020; 583: 437-440.
[21]. Perlman S. COVID-19 poses a riddle for the immune system. Nature. 2020; 584: 345-346.
[22]. Giamarellos-Bourboulis E J,Netea M G,Rovina N,Akinosoglou K,Antoniadou A,Antonakos N, et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020; 27: 992-1000.e1003.
[23]. Varchetta S,Mele D,Oliviero B,Mantovani S,Ludovisi S,Cerino A, et al. Unique immunological profile in patients with COVID-19. Cell Mol Immunol. 2021; 18: 604-612.
[24]. Yao C,Bora S A,Parimon T,Zaman T,Friedman O A,Palatinus J A, et al. Cell-Type-Specific Immune Dysregulation in Severely Ill COVID-19 Patients. Cell Rep. 2021; 34: 108590.
[25]. Khadke S,Ahmed N,Ahmed N,Ratts R,Raju S,Gallogly M, et al. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virol J. 2020; 17: 154.
[26]. Ebihara T,Masuda H,Akazawa T,Shingai M,Kikuta H,Ariga T, et al. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection. International Immunology. 2007; 19: 1145-1155.
[27]. Diab M,Schmiedel D,Seidel E,Bacharach E,Mandelboim O. Human Metapneumovirus Escapes NK Cell Recognition through the Downregulation of Stress-Induced Ligands for NKG2D. Viruses. 2020; 12.
[28]. Fink A,Mikuličić S,Blaum F,Reddehase M J,Florin L,Lemmermann N A W. Function of the cargo sorting dileucine motif in a cytomegalovirus immune evasion protein. Medical Microbiology and Immunology. 2019; 208: 531-542.
[29]. Goodnow C C. COVID-19, varying genetic resistance to viral disease and immune tolerance checkpoints. Immunol Cell Biol. 2021; 99: 177-191.